Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00992602 · ClinicalTrials.gov registry record · Phase 2
Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00992602 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 3 participants.
The verdict
NCT00992602, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial studies how well giving liposomal cytarabine and high-dose methotrexate works in treating patients with breast cancer that has spread to the central nervous system. Drugs used in chemotherapy, such as liposomal cytarabine and methotrexate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving liposomal cytarabine with high-dose methotrexate may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- OTHER quality-of-life assessment
- DRUG methotrexate
- DRUG liposomal cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00992602
The ClinicalTrials.gov registry entry for NCT00992602 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00992602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00992602 about?
NCT00992602 is a clinical study titled "Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer". This phase II trial studies how well giving liposomal cytarabine and high-dose methotrexate works in treating patients with breast cancer that has spread to the central nervous system. Drugs used in chemotherapy, such as liposomal cytarabine and methotrexate, work in different ways to stop the growt...
What is the current status of trial NCT00992602?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2011-04. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00992602?
The interventions under investigation include: laboratory biomarker analysis (OTHER), quality-of-life assessment (OTHER), methotrexate (DRUG), liposomal cytarabine (DRUG).
Who is sponsoring clinical trial NCT00992602?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.